“The results of our study have demonstrated good tolerance and promising efficacy, particularly in controlling disease progression in patients with advanced sarcoma,” stated Lanzafame. https://t.co/bfQtTkm19T #SarcomaAwarenessMonth #SarcomaAwareness #RadOnc